Skip to main content


Fig. 2 | Radiation Oncology

Fig. 2

From: Idelalisib may have the potential to increase radiotherapy side effects

Fig. 2

Individual radiosensitivity testing of the patients lymphocytes under Idelalisib compared to different control groups. Three-color FISH painting of chromosomes 1 (red), 2 (green) and 4 (yellow). a A metaphase without aberrations, b a metaphase with one translocation and one acentric fragment and c a metaphase with one insertion and two acentric fragments are displayed. The aberrations were scored as 3 breaks per metaphase (B/M) and 5 (B/M). d Lymphocytes of a healthy individual were irradiated in vitro with 2 Gy and 10 nmol/l or 1 μmol/l Idelalisib and were compared to a control without Idelalisib treatment. e Lymphocytes were irradiated ex vivo with 2 Gy. B/M found in nonirradiated metaphases were subtracted from those scored in the irradiated samples. The patients individual radiosensitivity is compared to groups of healthy controls, cancer patients and radiosensitive patients

Back to article page